ITEK Inotek Pharmaceuticals Corp

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Inotek Pharmaceuticals Corporation

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) (“Inotek”) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On January 3, 2017, Inotek announced disappointing results for its Phase 3 pivotal trial of trabodenson for the treatment of primary open-angle glaucoma or ocular hypertension. The study failed to meet its primary endpoint due to “a placebo response that was… greater than that observed in Phase 2.” To obtain additional information, go to:

http://zlk.9nl.com/inotek-pharmaceuticals-itek

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
04/01/2017

Underlying

ITEKInotek Pharmaceuticals Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Inotek Pharmaceuticals Corp

 PRESS RELEASE
Free
ITEK Inotek Pharmace...

Inotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement...

LEXINGTON, Mass. & NEW YORK, NY--(BUSINESS WIRE)-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) today announced the filing with the US Securities and Exchange Commission (SEC) of the Company’s preliminary proxy statement in connection with the previously announced proposed combination of Inotek Pharmaceuticals and Rocket Pharmaceuticals, a leading US-based multi-platform gene therapy company (the Merger). “We believe the proposed merger with Rocket provides an attractive opportunity for our shareholders,” said Dav...

October 12, 2017 1 EN
 PRESS RELEASE
Free
ITEK Inotek Pharmace...

INSERTING and REPLACING Inotek Pharmaceuticals Announces Merger Agreem...

LEXINGTON, Mass & NEW YORK--(BUSINESS WIRE)-- Insert after Rocket Pharmaceuticals, Ltd. boilerplate, fourth sentence: The Company is backed by leading institutional investors, including RTW Investments, Cormorant Asset Management and Tavistock Group. The corrected release reads: Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases - Company to Leverage Lentiviral and AAV Gene Therapy Platforms to Target Rar...

September 12, 2017 1 EN
 PRESS RELEASE
Free
ITEK Inotek Pharmace...

Inotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financi...

LEXINGTON, Mass.--(BUSINESS WIRE)-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, including glaucoma, today reported financial results and operational highlights for the quarter ended June 30, 2017. “Inotek recently announced top-line results from our Phase 2 fixed-dosed combination (FDC) trial of trabodenoson, which did not show a clinically meaningful advantage of intraocular p...

August 3, 2017 1 EN
 PRESS RELEASE
Free
ITEK Inotek Pharmace...

Inotek Pharmaceuticals Announces Top-line Results of Phase 2 Fixed-dos...

LEXINGTON, Mass.--(BUSINESS WIRE)-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced top-line results of the Phase 2 fixed-dose combination (FDC) trial of trabodenoson and latanoprost for the treatment of glaucoma. The trial was designed to assess the benefit/risk profile of the different fixed-dose combinations being evaluated. It was not powered for statistical differences ...

July 7, 2017 1 EN
 PRESS RELEASE
Free
ITEK Inotek Pharmace...

Inotek Pharmaceuticals Corporation Reports First Quarter 2017 Financia...

LEXINGTON, Mass.--(BUSINESS WIRE)-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today reported financial results and operational highlights for the quarter ended March 31, 2017. “Our Phase 2 fixed-dose combination (FDC) trial of trabodenoson and latanoprost is ongoing, and we recently completed the active recruitment phase,” said David P. Southwell, President and Chief E...

May 10, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch